Clinical Trials
Prevention of Iron Deficiency Anaemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research
Principal Investigator: Dr. Rashidul Haque,MBBS, Ph.D Senior Scientist and PI Infectious Diseases Division, icddr,bCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 6 Nov, 2022
Bioequivalence Study of Test Product Linagliptin 2.5mg and Metformin 1000 mg tablet of Beximco Pharmaceutical ltd Bangladesh comparing with reference product Trajentamet tablet 2.5mg/1000 mg containing Linagliptin and metformain hydrochloride 2.5/1000mg of Boheringer Ingelheim Pty ltd in healthy adult subjects under fasting conditions .
Principal Investigator: Prof. Dr. Liaquat AliCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 31 Oct, 2022
Does additional Clofazimine for smear-positive Multi Bacillary Border Line and Leprometus Leprosy cases at high risk of Erythema Nodosum Leprosum reactions improve their prognosis/ outcome over 2 years?
Principal Investigator: Dr. V V PaiCRO: Leprosy Mission International
Application Date: 13 Sep, 2022
An Open label, single dose, single treatment, single period, safety and bioavailability study of Fexofenadine Hydrochloride tropical lotion 1% in healthy, adult, male human subjects.
Principal Investigator: Dr Wasif Ali Khan, Scientist, icddrbCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 5 Jul, 2022
A Randomised control, double blinded, non inferiority trial to evaluate the immunogenicity and safety of Typhoid Vi conjugate vaccine, 'Typhocon' in Bangladeshi healthy population
Principal Investigator: InceptaCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 26 Jun, 2022
A Randomised control, double blinded, non inferiority trial to evaluate the immunogenicity and safety of Typhoid Vi conjugate vaccine, 'Typhocon' in Bangladeshi healthy population
Principal Investigator: Dr. Farhana Khanam icddr,bCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 23 Jun, 2022
A randomized control, double blinded, non inferiority trial to evaluate the immunogenicity and safety of Typhoid Vi Conjugate Vaccine 'Typhocon' in Bangladeshi healthy population
Principal Investigator: Dr. Farhana Khanam Infectious Disease Division icddr,bCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 22 Jun, 2022
A Phase 2/3. Randomized. Observer-Blind. Placebo-Controlled study to evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine targeting Respiratory Syncytial Virus (RSV), in Adults >=60 Years of Age
Principal Investigator: Dr. K Zaman MBBS, MPH, PhD, FRCP Edin Principal Investigator and Senior Scientist Infectious Diseases DivisionCRO: International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b).
Application Date: 8 Jun, 2022
A Randomized, Multiple-Dose, Three-Treatment, Active Controlled, Comparatively Safety and Efficacy Study of Cyclobenzaprine Nasal Spray in Subjects with Pain Due to Lower Back or Neck Muscle Spasm Associated with Acute Painful Musculoskeletal Conditions
Principal Investigator: Dr. Md. Azizul HaqueCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 6 Jun, 2022
"Bioequivalence study of test product Empagliflozin 25 mg Tablet of Beximco Pharmaceuticals Limited, Bangladesh with reference product Jardiance 25 mg (Empagliflozin 25 mg) Tablet of Boehringer Ingelheim Pharmaceuticals Pty Limited Sydney, Australia(Boehringer Ingelheim N.Z. Limited Auckland) in healthy adult human subjects under fasting conditions,
Principal Investigator: Urmi Lohani Lead Clinical ResearcherCRO: M/S. Novas Clinical Research Services Ltd. (NCRSL),
Application Date: 26 May, 2022
Showing 31 to 40 of 65 results
Login with Facebook
Login with Google